Skip to main content
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Access every election story that matters
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
// //

A nurse shows Russia's Sputnik V COVID-19 vaccine at a clinic in Moscow, on Sept. 17, 2020.

TATYANA MAKEYEVA/Reuters

Russian journalists working for two state-owned media outlets are among the first to be offered the new Sputnik V COVID-19 vaccine outside of the framework of a clinical trial, according to one of the outlets and four employees.

Russia began vaccinating members of the general public seen at high risk of coronavirus infection earlier this month, while separately launching a large-scale trial. So far about 400 people have received the jabs under that scheme, the health ministry said this week.

The government last month published a list of jobs considered high risk, which included health workers, journalists and teachers.

Story continues below advertisement

With hundreds of potential COVID-19 vaccines in various stages of development around the world, Russia was the first country to license its vaccine for public use and alongside China has been deploying the shots before full efficacy trials are complete.

Two journalists at the state-run RIA news agency and two at the Russian state television holding company VGTRK, which operates Russia-1 and Russia-24 news channels, told Reuters they had been offered a COVID-19 shot on a voluntary basis.

One of the RIA journalists said his impression was that the majority of his colleagues had declined the offer. One of the VGTRK journalists also said many of his colleagues declined.

The RIA news agency confirmed the inoculation program. “We granted employees who constantly work from the office (not remotely), at events, and in the field, the option to receive a Sputnik V vaccination,” it said in a statement.

RIA did not say how many employees received the vaccine and VGTRK did not respond to a request for comment. Both companies employ hundreds of people.

At RIA and VGTRK headquarters in Moscow, media workers who spoke to Reuters said they had a basic medical checkup and coronavirus PCR and antibody tests.

In an interview with Reuters, the chief scientist behind the vaccine’s development said people vaccinated outside of a trial undergo a less rigorous medical examination, though they can submit additional health data via an online platform.

Story continues below advertisement

At the time of its registration, the vaccine had been tested officially on fewer than 100 volunteers as part of early-stage clinical trials. Late stage trials began last month, with the first volunteer of a 40,000-strong cohort vaccinated on Sept. 9.

Our Morning Update and Evening Update newsletters are written by Globe editors, giving you a concise summary of the day’s most important headlines. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies